Parenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility Study
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 years;
• Admitted to an ICU with one or more of the following:
‣ Non-invasive ventilation (including CPAP, Bipap and high flow oxygen (\>10L/min) or invasive mechanical ventilation with an expected duration \>24 hours for respiratory failure (hypercarbic or hypoxic)
⁃ Vasopressor or inotropic support with an expected duration of \>24 hours
⁃ Cardiac arrest
• Continuous cardiac monitoring.
Locations
Other Locations
Canada
St Joseph's Healthcare Hamilton
NOT_YET_RECRUITING
Hamilton
Kingston Health Sciences Centre
RECRUITING
Kingston
The Ottawa Hospital - Civic Campus
NOT_YET_RECRUITING
Ottawa
The Ottawa Hospital - General Campus
NOT_YET_RECRUITING
Ottawa
Contact Information
Primary
Miranda Hunt
miranda.hunt@kingstonhsc.ca
613 549 6666
Time Frame
Start Date: 2023-08-20
Estimated Completion Date: 2028-07-01
Participants
Target number of participants: 200
Treatments
Experimental: Magnesium Sulfate
4g Magnesium sulfate (100mL) BID, given intravenously over 2 hours, for a total of 10 doses
Placebo_comparator: 0.9% NaCl
100mL 0.9% NaCl BID, given intravenously over 2 hours, for a total of 10 doses
Related Therapeutic Areas
Sponsors
Collaborators: Canadian Institutes of Health Research (CIHR), Southeastern Ontario Academic Medical Organization (SEAMO)
Leads: Dr. Stephanie Sibley